PL3456717T3 - Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej - Google Patents

Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej

Info

Publication number: PL3456717T3
Authority: PL; Poland
Prior art keywords: cot; diamino; quinoline; modulator; inflammatory disease
Prior art date: 2015-07-06

Application number

PL18186568T

Other languages

English (en)

Polish (pl)

Inventor

Elizabeth M. Bacon

Gayatri BALAN

Chien-Hung Chou

Christopher T. Clark

Jeromy J. Cottell

Musong Kim

Thorsten A. Kirschberg

John O. Link

Gary Phillips

Scott D. Schroeder

Neil H. Squires

Kirk L. Stevens

James G. Taylor

William J. Watkins

Nathan E. Wright

Sheila M. Zipfel

Original Assignee

Gilead Sciences, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-06-30

Publication date

2021-10-25

2016-06-30 Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.

2021-10-25 Publication of PL3456717T3 publication Critical patent/PL3456717T3/pl

Links

WATPKLRWBYNCDK-UHFFFAOYSA-N 4,6-diaminoquinoline-3-carbonitrile Chemical class N1=CC(C#N)=C(N)C2=CC(N)=CC=C21 WATPKLRWBYNCDK-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
210000001685 thyroid gland Anatomy 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Obesity (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Nutrition Science (AREA)
Gastroenterology & Hepatology (AREA)

PL18186568T 2015-07-06 2016-06-30 Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej PL3456717T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562189158P	2015-07-06	2015-07-06
US201562269060P	2015-12-17	2015-12-17
PCT/US2016/040520 WO2017007689A1 (en)	2015-07-06	2016-06-30	Cot modulators and methods of use thereof
EP18186568.4A EP3456717B1 (en)	2015-07-06	2016-06-30	4,6-diamino-quinoline-3-carbonitrile derivative as cancer osaka thyroid (cot) modulator for treating inflammatory disease
EP16738976.6A EP3191470B1 (en)	2015-07-06	2016-06-30	Cot modulators and methods of use thereof

Publications (1)

Publication Number	Publication Date
PL3456717T3 true PL3456717T3 (pl)	2021-10-25

Family

ID=56411943

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL18186568T PL3456717T3 (pl)	2015-07-06	2016-06-30	Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
PL16738976T PL3191470T3 (pl)	2015-07-06	2016-06-30	Modulatory Cot i sposoby ich zastosowania
PL21162393.9T PL3896064T3 (pl)	2015-07-06	2016-06-30	Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL16738976T PL3191470T3 (pl)	2015-07-06	2016-06-30	Modulatory Cot i sposoby ich zastosowania
PL21162393.9T PL3896064T3 (pl)	2015-07-06	2016-06-30	Pochodne 4,6-diamino-chinolino-3-karbonitrylu jako modulatory cot w leczeniu choroby leśniowskiego-crohna i wrzodziejącego zapalenia jelita grubego

Country Status (41)

Country	Link
US (8)	US20170008905A1 (2)
EP (4)	EP4613332A3 (2)
JP (6)	JP6430060B2 (2)
KR (5)	KR102443575B1 (2)
CN (4)	CN119143730A (2)
AU (5)	AU2016290820B2 (2)
BR (1)	BR102016015656B1 (2)
CA (1)	CA2971640C (2)
CL (1)	CL2017003356A1 (2)
CO (1)	CO2017013351A2 (2)
CR (1)	CR20170599A (2)
CU (1)	CU20170172A7 (2)
CY (1)	CY1121750T1 (2)
DK (1)	DK3191470T3 (2)
DO (1)	DOP2017000311A (2)
EA (1)	EA036788B1 (2)
EC (1)	ECSP17084635A (2)
ES (3)	ES2872076T3 (2)
HR (1)	HRP20190853T1 (2)
HU (1)	HUE043310T2 (2)
IL (4)	IL293770B2 (2)
LT (1)	LT3191470T (2)
MA (1)	MA39422B1 (2)
ME (1)	ME03425B (2)
MX (1)	MX370984B (2)
MY (1)	MY196173A (2)
NZ (2)	NZ738525A (2)
PE (1)	PE20180462A1 (2)
PH (2)	PH12018500031B1 (2)
PL (3)	PL3456717T3 (2)
PT (3)	PT3896064T (2)
RS (1)	RS58639B1 (2)
SA (1)	SA517381350B1 (2)
SG (1)	SG11201702041PA (2)
SI (3)	SI3191470T1 (2)
SM (1)	SMT201900244T1 (2)
SV (1)	SV2017005605A (2)
TW (3)	TWI748539B (2)
UA (1)	UA123010C2 (2)
UY (1)	UY36771A (2)
WO (1)	WO2017007689A1 (2)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012278976B2 (en)	2011-07-06	2017-05-11	Gilead Sciences, Inc.	Compounds for the treatment of HIV
US10118890B2 (en)	2014-10-10	2018-11-06	The Research Foundation For The State University Of New York	Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
PL3456717T3 (pl)	2015-07-06	2021-10-25	Gilead Sciences, Inc.	Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
NZ738538A (en)	2015-07-06	2019-06-28	Gilead Sciences Inc	6-amino-quinoline-3-carbonitrils as cot modulators
CA3029457A1 (en)	2016-06-30	2018-01-04	Gilead Sciences, Inc.	4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN119462611A (zh) *	2016-08-19	2025-02-18	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
EA036921B1 (ru) *	2017-02-10	2021-01-15	Джилид Сайэнс, Инк.	Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) *	2017-04-26	2018-11-13	上海时莱生物技术有限公司	硼酸和硼酸酯类化合物及其制备方法和用途
TWI687415B (zh)	2017-08-17	2020-03-11	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
EP3689866A4 (en) *	2017-09-26	2021-07-07	Nippon Soda Co., Ltd.	QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE
JP7083398B2 (ja)	2018-02-15	2022-06-10	ギリアードサイエンシーズ，インコーポレイテッド	ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (en)	2018-02-16	2023-07-05	Gilead Sciences, Inc.	Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
WO2019168874A1 (en)	2018-02-27	2019-09-06	The Research Foundation For The State University Of New York	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) *	2018-03-23	2021-09-24	中国农业大学	一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) *	2018-06-25	2018-10-16	中国药科大学	一种氘代Fiduxosin的制备方法
KR20210033492A (ko)	2018-07-16	2021-03-26	길리애드 사이언시즈, 인코포레이티드	Hiv의 치료를 위한 캡시드 억제제
TWI770527B (zh) *	2019-06-14	2022-07-11	美商基利科學股份有限公司	Cot 調節劑及其使用方法
WO2021028323A1 (en)	2019-08-09	2021-02-18	Idorsia Pharmaceuticals Ltd	(2-acetamidyl)thio-beta-d-galactopyranoside derivatives
CN114206893A (zh)	2019-08-09	2022-03-18	爱杜西亚药品有限公司	(杂)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物
MA56883B1 (fr)	2019-08-15	2025-04-30	Idorsia Pharmaceuticals Ltd	Dérivés de 2-hydroxycycloalcane-1-carbamoyle
CN114585619B (zh)	2019-08-29	2024-09-27	爱杜西亚药品有限公司	α-D-吡喃半乳糖苷衍生物
CA3157275C (en)	2019-11-26	2026-02-10	Gilead Sciences, Inc.	Capsid inhibitors for the prevention of hiv
CA3175541A1 (en) *	2020-03-30	2021-10-07	Gilead Sciences, Inc.	Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja) *	2020-04-02	2024-03-08	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｏｔ阻害剤化合物を調製するためのプロセス
TWI858267B (zh)	2020-06-25	2024-10-11	美商基利科學股份有限公司	用於治療hiv之蛋白殼抑制劑
US12312362B2 (en)	2020-10-06	2025-05-27	Idorsia Pharmaceuticals Ltd	Spiro derivatives of Alpha-D-galactopyranosides
EP4237419A1 (en)	2020-11-02	2023-09-06	Idorsia Pharmaceuticals Ltd	Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh)	2021-02-09	2023-09-26	爱杜西亚药品有限公司	羟基杂环烷-氨甲酰基衍生物
RS67032B1 (sr)	2021-03-03	2025-08-29	Idorsia Pharmaceuticals Ltd	Alfa-d-galaktopiranozidni derivati supstituisani triazolil-metilom
TW202345826A (zh) *	2021-06-04	2023-12-01	美商基利科學股份有限公司	治療nash之方法
US20240285646A1 (en) *	2021-06-11	2024-08-29	Neuronascent, Inc.	Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
CR20240223A (es)	2021-12-03	2024-07-08	Gilead Sciences Inc	Compuestos terapéuticos para la infección por el virus del vih
US12404262B2 (en)	2021-12-03	2025-09-02	Gilead Sciences, Inc.	Therapeutic compounds for HIV virus infection
US12084467B2 (en)	2021-12-03	2024-09-10	Gilead Sciences, Inc.	Therapeutic compounds for HIV virus infection
WO2024245157A1 (zh) *	2023-05-30	2024-12-05	浙江星浩澎博医药有限公司	氮杂喹啉环衍生物
EP4719412A1 (en) *	2023-06-02	2026-04-08	Westol, LLC	2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications
WO2025020886A1 (zh) *	2023-07-27	2025-01-30	浙江星浩澎博医药有限公司	氮杂喹唑啉环衍生物及其用途
KR102732584B1 (ko)	2024-03-28	2024-11-21	(주)신한티이씨	전기 배전반의 화재 위험 감지 및 진압용 소화 장치

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3930837A (en)	1971-12-31	1976-01-06	Ici Australia Limited	3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4151298A (en)	1977-01-10	1979-04-24	Ciba-Geigy Corporation	Anthelmintic compositions
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja)	1988-07-26	1997-07-23	三井東圧化学株式会社	不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de)	1990-05-03	1991-11-07	Basf Ag	Cyanochinolinverbindungen
GB9310700D0 (en)	1993-05-24	1993-07-07	Zeneca Ltd	Novel composition
UA73073C2 (uk) *	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
WO1999011124A1 (fr)	1997-08-28	1999-03-11	Nissan Chemical Industries, Ltd.	Agents antibacteriens et antifongiques, algicides et agents antisalissure a base de cyanoacrylate, a usage industriel
CA2336691C (en)	1998-07-10	2009-02-10	Massachusetts Institute Of Technology	Ligands for metals and metal-catalyzed processes
IL142092A0 (en)	1998-09-29	2002-03-10	American Cyanamid Co	Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GEP20074230B (en)	2002-03-20	2007-11-12	Bristol Myers Squibb Co	Phosphate prodrugs of fluorooxindoles
KR100751604B1 (ko)	2003-03-03	2007-08-22	에프. 호프만-라 로슈 아게	5-ｈｔ6 조절자로서 사용되는 2,5- 및 2,6-치환된테트라하이드로아이소퀴놀린
CN1835923A (zh)	2003-08-19	2006-09-20	惠氏控股公司	制备4－氨基－3－喹啉腈的方法
US7399865B2 (en) *	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) *	2004-02-20	2005-09-16	Wyeth Corp	3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
EP1888529A2 (en) *	2005-05-18	2008-02-20	Wyeth	3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
MX2007014258A (es)	2005-05-18	2008-01-22	Wyeth Corp	Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos.
CN101365684A (zh)	2005-10-28	2009-02-11	艾博特公司	抑制trpv1受体的吲唑衍生物
CA2644910C (en)	2006-03-31	2014-01-28	Abbott Laboratories	Indazole compounds
ES2481442T3 (es)	2006-11-09	2014-07-30	Probiodrug Ag	Inhibidores novedosos de glutaminil ciclasa
CN101583601B (zh)	2007-01-17	2013-06-05	香港科技大学	作为褪黑素受体mt1和mt2的亚型选择性激动剂的异喹诺酮化合物
GB0820856D0 (en)	2008-11-14	2008-12-24	Univ Leuven Kath	Novel inhibitors of flavivirus replication
TWI598347B (zh)	2009-07-13	2017-09-11	基利科學股份有限公司	調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) *	2009-12-22	2010-02-03	Imp Innovations Ltd	Compounds
BR112012022801B8 (pt)	2010-03-09	2019-10-29	Dana Farber Cancer Inst Inc	método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
EP2581372B1 (en)	2010-06-09	2017-06-07	Tianjin Hemay Oncology Pharmaceutical Co., Ltd.	Cyanoquinoline derivatives
EP2708540B1 (en)	2011-05-10	2018-07-25	Kyowa Hakko Kirin Co., Ltd.	Pyrimido-diazepinone compound
JP2014520776A (ja)	2011-07-04	2014-08-25	バイエル・インテレクチユアル・プロパテイー・ゲー・エム・ベー・ハー	植物における非生物的ストレスに対する活性薬剤としての置換されているイソキノリノン類、イソキノリンジオン類、イソキノリントリオン類およびジヒドロイソキノリノン類または各場合でのそれらの塩の使用
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
WO2013062027A1 (ja)	2011-10-27	2013-05-02	大正製薬株式会社	アゾール誘導体
RS57157B1 (sr)	2011-11-11	2018-07-31	Gilead Apollo Llc	Acc inhibitori i njihove primene
UY34573A (es)	2012-01-27	2013-06-28	Gilead Sciences Inc	Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh)	2012-06-13	2016-12-21	上海赛迦化工产品有限公司	多样性的手性氨基硼酸及其制备方法和应用
US20150297573A1 (en)	2012-10-24	2015-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103408572B (zh)	2013-07-12	2015-12-02	上海工程技术大学	手性氨基硼酸衍生物及其制备方法和应用
CA2932039A1 (en)	2013-12-12	2015-06-18	Kalyra Pharmaceuticals, Inc.	Bicyclic alkyl compounds and synthesis
CN113336653A (zh)	2014-03-07	2021-09-03	里科瑞尔姆Ip控股有限责任公司	螺桨烷衍生物及合成
US9701661B2 (en) *	2014-07-11	2017-07-11	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
US10308609B2 (en)	2014-09-17	2019-06-04	Zeno Royalties & Milestones, LLC	Bicyclic compounds
MX2017003933A (es)	2014-09-24	2017-06-30	Gilead Sciences Inc	Metodos de tratamiento de la enfermedad hepatica.
CN112225699B (zh)	2014-12-23	2023-11-14	吉利德科学公司	制备ask1抑制剂的方法
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
EA201791258A1 (ru)	2015-01-09	2017-12-29	Джилид Аполло, Ллс	Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
WO2016115002A1 (en)	2015-01-16	2016-07-21	3M Innovative Properties Company	Systems and methods for selecting grid actions to improve grid outcomes
PL3456717T3 (pl)	2015-07-06	2021-10-25	Gilead Sciences, Inc.	Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
NZ738538A (en)	2015-07-06	2019-06-28	Gilead Sciences Inc	6-amino-quinoline-3-carbonitrils as cot modulators
EP3398598B1 (en)	2015-12-31	2022-04-06	Hitgen Inc.	Sulfonamide derivative and preparation method and use thereof
SG11201807077RA (en)	2016-03-02	2018-09-27	Gilead Apollo Llc	Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof
WO2017221944A1 (ja)	2016-06-21	2017-12-28	パナソニックヘルスケアホールディングス株式会社	カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法
CA3029457A1 (en)	2016-06-30	2018-01-04	Gilead Sciences, Inc.	4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN106512014A (zh)	2016-10-27	2017-03-22	武汉大学	肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CN110382503B (zh)	2017-03-03	2022-07-19	吉利德科学公司	制备acc抑制剂及其固体形式的方法
SI4122464T1 (sl)	2017-03-28	2024-07-31	Gilead Sciences, Inc.	Terapevtske kombinacije za zdravljenje bolezni jeter
JP2020516627A (ja)	2017-04-12	2020-06-11	ギリアードサイエンシーズ，インコーポレイテッド	肝疾患を処置する方法
US10980810B2 (en)	2017-10-06	2021-04-20	Gilead Sciences, Inc.	Combination therapy comprising an ACC inhibitor
JP2022519906A (ja)	2019-02-19	2022-03-25	ギリアードサイエンシーズ，インコーポレイテッド	Ｆｘｒアゴニストの固体形態
WO2020185685A1 (en)	2019-03-08	2020-09-17	The Regents Of The University Of California	Compositions and methods for treating acne
TWI770527B (zh)	2019-06-14	2022-07-11	美商基利科學股份有限公司	Cot 調節劑及其使用方法
AR119594A1 (es)	2019-08-09	2021-12-29	Gilead Sciences Inc	Derivados de tienopirimidina como inhibidores acc y usos de los mismos
CA3175541A1 (en)	2020-03-30	2021-10-07	Gilead Sciences, Inc.	Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
JP7446475B2 (ja)	2020-04-02	2024-03-08	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｏｔ阻害剤化合物を調製するためのプロセス
TW202345826A (zh)	2021-06-04	2023-12-01	美商基利科學股份有限公司	治療nash之方法

2016
- 2016-06-30 PL PL18186568T patent/PL3456717T3/pl unknown
- 2016-06-30 AU AU2016290820A patent/AU2016290820B2/en active Active
- 2016-06-30 HR HRP20190853TT patent/HRP20190853T1/hr unknown
- 2016-06-30 ME MEP-2019-117A patent/ME03425B/me unknown
- 2016-06-30 SI SI201630202T patent/SI3191470T1/sl unknown
- 2016-06-30 PL PL16738976T patent/PL3191470T3/pl unknown
- 2016-06-30 NZ NZ738525A patent/NZ738525A/en unknown
- 2016-06-30 US US15/199,534 patent/US20170008905A1/en not_active Abandoned
- 2016-06-30 KR KR1020207002878A patent/KR102443575B1/ko active Active
- 2016-06-30 CN CN202411260421.8A patent/CN119143730A/zh active Pending
- 2016-06-30 EP EP25176778.6A patent/EP4613332A3/en active Pending
- 2016-06-30 WO PCT/US2016/040520 patent/WO2017007689A1/en not_active Ceased
- 2016-06-30 UA UAA201712984A patent/UA123010C2/uk unknown
- 2016-06-30 PT PT211623939T patent/PT3896064T/pt unknown
- 2016-06-30 KR KR1020187003221A patent/KR101974793B1/ko active Active
- 2016-06-30 NZ NZ750707A patent/NZ750707A/en unknown
- 2016-06-30 MX MX2017004737A patent/MX370984B/es active IP Right Grant
- 2016-06-30 CU CUP2017000172A patent/CU20170172A7/xx unknown
- 2016-06-30 HU HUE16738976A patent/HUE043310T2/hu unknown
- 2016-06-30 EP EP21162393.9A patent/EP3896064B1/en active Active
- 2016-06-30 EA EA201792613A patent/EA036788B1/ru unknown
- 2016-06-30 KR KR1020197011792A patent/KR102073641B1/ko active Active
- 2016-06-30 PT PT181865684T patent/PT3456717T/pt unknown
- 2016-06-30 IL IL293770A patent/IL293770B2/en unknown
- 2016-06-30 ES ES18186568T patent/ES2872076T3/es active Active
- 2016-06-30 PE PE2017002804A patent/PE20180462A1/es unknown
- 2016-06-30 IL IL274568A patent/IL274568B/en unknown
- 2016-06-30 ES ES21162393T patent/ES3034100T3/es active Active
- 2016-06-30 EP EP18186568.4A patent/EP3456717B1/en active Active
- 2016-06-30 DK DK16738976.6T patent/DK3191470T3/en active
- 2016-06-30 CA CA2971640A patent/CA2971640C/en active Active
- 2016-06-30 JP JP2018500585A patent/JP6430060B2/ja active Active
- 2016-06-30 MY MYPI2018700007A patent/MY196173A/en unknown
- 2016-06-30 ES ES16738976T patent/ES2734713T3/es active Active
- 2016-06-30 CR CR20170599A patent/CR20170599A/es unknown
- 2016-06-30 LT LTEP16738976.6T patent/LT3191470T/lt unknown
- 2016-06-30 EP EP16738976.6A patent/EP3191470B1/en active Active
- 2016-06-30 RS RS20190498A patent/RS58639B1/sr unknown
- 2016-06-30 SG SG11201702041PA patent/SG11201702041PA/en unknown
- 2016-06-30 CN CN201680050602.5A patent/CN107922390B/zh active Active
- 2016-06-30 SI SI201631907T patent/SI3896064T1/sl unknown
- 2016-06-30 MA MA39422A patent/MA39422B1/fr unknown
- 2016-06-30 KR KR1020227031078A patent/KR20220129667A/ko not_active Ceased
- 2016-06-30 CN CN202210008753.1A patent/CN114380799B/zh active Active
- 2016-06-30 CN CN201910292757.5A patent/CN109879859B/zh active Active
- 2016-06-30 PT PT16738976T patent/PT3191470T/pt unknown
- 2016-06-30 SI SI201631197T patent/SI3456717T1/sl unknown
- 2016-06-30 SM SM20190244T patent/SMT201900244T1/it unknown
- 2016-06-30 PL PL21162393.9T patent/PL3896064T3/pl unknown
- 2016-06-30 KR KR1020247000058A patent/KR20240008398A/ko not_active Ceased
- 2016-07-04 BR BR102016015656-4A patent/BR102016015656B1/pt active IP Right Grant
- 2016-07-05 TW TW109122003A patent/TWI748539B/zh active
- 2016-07-05 TW TW105121281A patent/TWI634112B/zh active
- 2016-07-05 TW TW107117905A patent/TWI699361B/zh active
- 2016-07-06 UY UY0001036771A patent/UY36771A/es not_active Application Discontinuation
2017
- 2017-02-09 US US15/429,086 patent/US9878995B2/en active Active
- 2017-04-18 SA SA517381350A patent/SA517381350B1/ar unknown
- 2017-12-20 IL IL256433A patent/IL256433B/en active IP Right Grant
- 2017-12-22 CO CONC2017/0013351A patent/CO2017013351A2/es unknown
- 2017-12-22 EC ECIEPI201784635A patent/ECSP17084635A/es unknown
- 2017-12-22 SV SV2017005605A patent/SV2017005605A/es unknown
- 2017-12-22 CL CL2017003356A patent/CL2017003356A1/es unknown
- 2017-12-26 DO DO2017000311A patent/DOP2017000311A/es unknown
2018
- 2018-01-03 PH PH12018500031A patent/PH12018500031B1/en unknown
- 2018-02-07 US US15/891,163 patent/US20180237455A1/en not_active Abandoned
- 2018-09-13 JP JP2018171794A patent/JP6781221B2/ja active Active
2019
- 2019-04-23 US US16/391,673 patent/US20190248807A1/en not_active Abandoned
- 2019-05-03 AU AU2019203122A patent/AU2019203122B2/en active Active
- 2019-05-20 CY CY20191100535T patent/CY1121750T1/el unknown
- 2019-05-29 IL IL266995A patent/IL266995B/en active IP Right Grant
- 2019-07-26 JP JP2019137759A patent/JP6906021B2/ja active Active
- 2019-12-17 US US16/717,074 patent/US11066414B2/en active Active
2020
- 2020-09-06 PH PH12020551397A patent/PH12020551397A1/en unknown
- 2020-10-20 AU AU2020257055A patent/AU2020257055B2/en active Active
- 2020-12-16 JP JP2020208330A patent/JP7138155B2/ja active Active
2021
- 2021-05-11 US US17/317,041 patent/US11905299B2/en active Active
2022
- 2022-04-11 JP JP2022065168A patent/JP2022082816A/ja not_active Withdrawn
- 2022-06-10 AU AU2022204050A patent/AU2022204050B2/en active Active
2023
- 2023-12-11 US US18/534,800 patent/US20240254137A1/en not_active Abandoned
2024
- 2024-05-17 JP JP2024081151A patent/JP2024100865A/ja not_active Withdrawn
- 2024-07-17 AU AU2024204902A patent/AU2024204902A1/en not_active Abandoned
2025
- 2025-04-14 US US19/177,702 patent/US20250346609A1/en active Pending

Also Published As

Publication number	Publication date
US20180237455A1 (en)	2018-08-23
TW201712005A (zh)	2017-04-01
KR20220129667A (ko)	2022-09-23
PE20180462A1 (es)	2018-03-06
AU2022204050B2 (en)	2024-04-18
CA2971640A1 (en)	2017-01-12
EA036788B1 (ru)	2020-12-21
AU2022204050A1 (en)	2022-06-30
CO2017013351A2 (es)	2018-05-21
US20200123172A1 (en)	2020-04-23
ME03425B (me)	2020-01-20
SA517381350B1 (ar)	2021-03-11
HUE043310T2 (hu)	2019-08-28
IL274568A (en)	2020-06-30
SI3456717T1 (sl)	2021-08-31
JP6430060B2 (ja)	2018-11-28
JP2018520161A (ja)	2018-07-26
ES2872076T3 (es)	2021-11-02
AU2020257055B2 (en)	2022-03-31
CR20170599A (es)	2018-02-28
JP2024100865A (ja)	2024-07-26
US20190248807A1 (en)	2019-08-15
JP2018193405A (ja)	2018-12-06
UA123010C2 (uk)	2021-02-03
PT3456717T (pt)	2021-05-26
TW202114673A (zh)	2021-04-16
NZ738525A (en)	2019-03-29
MX370984B (es)	2020-01-09
KR20240008398A (ko)	2024-01-18
CN119143730A (zh)	2024-12-17
IL274568B (en)	2022-07-01
PT3896064T (pt)	2025-07-03
DOP2017000311A (es)	2018-01-15
SI3191470T1 (sl)	2019-04-30
TWI634112B (zh)	2018-09-01
KR101974793B1 (ko)	2019-05-02
EP3456717A1 (en)	2019-03-20
JP2019178178A (ja)	2019-10-17
SMT201900244T1 (it)	2019-05-10
TWI699361B (zh)	2020-07-21
AU2020257055A1 (en)	2020-11-12
CN107922390B (zh)	2019-05-10
US20170008905A1 (en)	2017-01-12
EA201792613A1 (ru)	2018-06-29
SI3896064T1 (sl)	2025-07-31
AU2016290820A1 (en)	2018-01-18
IL293770B1 (en)	2023-03-01
KR20190045416A (ko)	2019-05-02
PL3191470T3 (pl)	2019-08-30
US20250346609A1 (en)	2025-11-13
CN109879859B (zh)	2022-01-25
IL266995B (en)	2020-05-31
NZ750707A (en)	2023-09-29
PH12018500031A1 (en)	2018-07-09
KR102073641B1 (ko)	2020-02-05
DK3191470T3 (en)	2019-04-15
CL2017003356A1 (es)	2018-07-06
BR102016015656B1 (pt)	2021-11-03
EP3456717B1 (en)	2021-03-17
MX2017004737A (es)	2017-06-19
JP6781221B2 (ja)	2020-11-04
AU2024204902A1 (en)	2024-08-01
SV2017005605A (es)	2018-07-18
IL293770B2 (en)	2023-07-01
HRP20190853T1 (hr)	2019-06-28
EP3896064A1 (en)	2021-10-20
LT3191470T (lt)	2019-05-10
AU2019203122B2 (en)	2020-10-01
TW201908305A (zh)	2019-03-01
CN109879859A (zh)	2019-06-14
UY36771A (es)	2017-01-31
IL293770A (en)	2022-08-01
IL256433A (en)	2018-02-28
ES3034100T3 (en)	2025-08-13
JP2022082816A (ja)	2022-06-02
IL266995A (en)	2019-07-31
US20170152240A1 (en)	2017-06-01
PH12020551397A1 (en)	2021-08-16
TWI748539B (zh)	2021-12-01
BR102016015656A2 (pt)	2020-09-24
US20240254137A1 (en)	2024-08-01
JP7138155B2 (ja)	2022-09-15
KR102443575B1 (ko)	2022-09-16
CU20170172A7 (es)	2018-06-05
US20230002407A1 (en)	2023-01-05
ECSP17084635A (es)	2018-01-31
KR20200013120A (ko)	2020-02-05
SG11201702041PA (en)	2017-04-27
WO2017007689A1 (en)	2017-01-12
MA39422A (fr)	2017-07-19
JP6906021B2 (ja)	2021-07-21
EP3896064B1 (en)	2025-05-21
CY1121750T1 (el)	2020-07-31
CN107922390A (zh)	2018-04-17
EP4613332A3 (en)	2025-12-10
IL256433B (en)	2019-06-30
MY196173A (en)	2023-03-17
CN114380799B (zh)	2024-10-01
CN114380799A (zh)	2022-04-22
US9878995B2 (en)	2018-01-30
MA39422B1 (fr)	2019-03-29
ES2734713T3 (es)	2019-12-11
EP3191470A1 (en)	2017-07-19
AU2016290820B2 (en)	2019-03-07
US11905299B2 (en)	2024-02-20
US11066414B2 (en)	2021-07-20
AU2019203122A1 (en)	2019-05-30
CA2971640C (en)	2020-09-22
KR20180022982A (ko)	2018-03-06
PL3896064T3 (pl)	2025-09-08
PT3191470T (pt)	2019-06-05
JP2021042252A (ja)	2021-03-18
EP3191470B1 (en)	2019-02-27
PH12018500031B1 (en)	2018-07-09
EP4613332A2 (en)	2025-09-10
RS58639B1 (sr)	2019-05-31

Publication	Publication Date	Title
PL3456717T3 (pl)	2021-10-25	Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
IL259693A (en)	2018-07-31	Preparations for topical administration and their use for the treatment of inflammation
IL252053A0 (en)	2017-07-31	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
PL2958945T3 (pl)	2023-01-09	Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
SG11201608764QA (en)	2016-11-29	Novel disubstituted 1, 2, 4-triazine compound
ZA201700019B (en)	2018-11-28	Substituted [1,2,4]triazole compounds
WO2014165090A8 (en)	2014-11-06	Compounds for the treatment of tuberculosis
ZA201706402B (en)	2019-01-30	C.novyi for the treatment of solid tumors in humans
EA201792612A1 (ru)	2018-07-31	6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EP3312170A4 (en)	2018-12-12	1,4-di-substituted imidazole derivative
GB201721287D0 (en)	2018-01-31	Treatment for inflammatory disease
PH12017501790A1 (en)	2018-04-02	Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EP3275450A4 (en)	2018-11-14	Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
PL3449135T3 (pl)	2022-03-28	Łącznik podwójny do połączenia na styk dwóch elementów konstrukcyjnych
SG11201803584RA (en)	2018-05-30	1,4-dicarbonyl-piperidyl derivatives
EP3268046A4 (en)	2018-11-21	Conjugates for treating diseases
PL3374357T3 (pl)	2020-05-18	Dipodstawione związki diaryloksybenzoheterodiazolowe
IL261329B (en)	2021-04-29	Radioactive drug complexes
IL244393A0 (en)	2016-04-21	A new derivative of 6,2-diaminopyrimidine
EP3273974A4 (en)	2018-11-07	Therapy for malignant disease
IL261958A (en)	2018-10-31	Formulations for treating constipation
IL258217A (en)	2018-05-31	2,3,4,5 tetrahydropyridin-6-amine derivatives
HUE053358T2 (hu)	2021-06-28	5-Metil-6-fenil-4,5-dihidro-2H-piridazin-3-on származék agytumorok kezelésére
IL243133B (en)	2018-07-31	Method for the preparation of (1,2,4)-triazolo(4,3-a)pyridines
LT3112575T (lt)	2019-02-11	Kištukinė jungtis